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upwards of 80% of the messenger
RNA for a particular gene and still
get a ‘normal’ plant, because
mRNA levels are not always
proportional to the amount of
protein actually produced (or
required). The possibility exists,
therefore, that the alterations in
gene expression observed in
polyploids are compensated for
at the translational level. Logic,
however, suggests that this is
probably not the case, because of
the phenotypic success of most
polyploids compared to their
progenitors, and recent evidence
from proteomic studies supports
this assumption. In a study of
synthetic Brassica allopolyploids,
Albertin et al. [20] discovered
a large number of proteins
displaying non-additive changes to
expression when compared to the
parental taxa (305 in stem, 200 in
root). They then undertook an
in silico gene expression analysis
to determine whether these
proteins were restricted to a
particular grouping, such as
cellular function and/or
localisation, and found that, as with
genes identified in transcriptional
expression studies, this was not
the case. Similarly, Albertin et al.
[20] found that different proteins
within the same complex could
have their expression altered in
opposing directions — again, as
observed in transcriptional studies.
Recent studies therefore
suggest that the process of
polyploidisation, whether
incorporating a hybridisation
event or not, has a large-scale
impact on gene expression in
the new individual, thereby
providing raw material upon
which selection can act. Small
wonder, then, that polyploid
species are so numerous — in
evolutionary terms, it would seem
that two genomes are indeed
better than one.
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of Genome-wide Associations
Genome-wide association studies are finally leading geneticists straight
to the genetic susceptibility factors for complex diseases. Several
challenges lie ahead, including translation of the findings into practical
public health outcomes, and integrating genetic analysis with broader
biological understanding.Greg Gibson1
and David B. Goldstein2
Human genetics is in the midst of a
revolution. Testing for association
between hundreds of thousands
of polymorphisms in several
thousand unrelated cases and
controls allows the genome to bescanned in an unbiased manner
for the major susceptibility variants
for complex diseases. Up until
eighteenmonths ago only a handful
of gene variants had been securely
associated with any common
diseases and the majority of
published claims of association
were at best unsubstantiated, but
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discoveries. Now that has all
changed. Real advances are
being made daily and the leading
journals weekly report the
discovery of multiple clearly
validated risk factors.
One recent example of this new
reality is the recent paper from the
Wellcome Trust Case Control
Consortium [1]. The Consortium
sought to scan the majority of the
human genome for some
contribution to seven common
diseases: bipolar disorder,
hypertension, coronary artery
disease, types 1 and 2 diabetes,
Crohn’s disease, and rheumatoid
arthritis. For each disease, half
a million single nucleotide
polymorphisms (SNPs) were
genotyped in 2,000 patients, and
the genotype frequencies were
compared with a common set of
3,000 controls, namely ‘healthy’
British subjects. The core result
was the identification of 24 highly
significant independent
association signals. Though not
reaching true experiment-wide
thresholds in all cases, these sites
nevertheless stick out like sore
thumbs against a mass of lesser
test statistics. Approximately half
of the associations have been
noted before, providing strong
validation for the approach. The
other half are novel, pinpointing
loci of interest for follow-up, and
eight of these have already been
independently replicated in new
cohorts.
For Crohn’s disease, type 2
diabetes, and breast cancer, we
now have multiple, multiply
validated SNPs that contribute at
least several percent each to
population attributable risk — let’s
call them parSNPs. If these variants
were not present in the human
genome, or if their effects could be
therapeutically ameliorated, there
would be a measurable reduction
in disease incidence. Once tens
of thousands of cases have been
sampled in a meta-analysis of
several studies, parSNPs that
provide a relative risk in the
vicinity of 1.2 — a twenty percent
increase in risk of contracting
the disease relative to
individuals with the protective
genotype — significance can
elevate to in excess of 10210,well beyond any reasonable
experiment-wise threshold. If they
don’t survive such analysis, either
they are false positives, perhaps
beneficiaries of the ‘winner’s curse’
of sampling bias that can inflate
estimates of risk, or they are
population-specific.
Genome-wide association
results are being widely heralded
[2] as a confirmation that many of
the precepts (and promises) of ‘big
science’ projects like the human
genome and HapMap projects are
being realized. After so many years
of frustration and disagreement in
the field, the sudden appearance
of both real discoveries and real
standards is most welcome.
Henceforth, claims that variation
in a particular gene contributes to
disease susceptibility must
demonstrate significance taking
into account all the hypotheses
that have been evaluated, andmust
be replicated using the same SNP
and the same phenotype [3].
Understandably, these standards
may percolate with different
speeds through the different
research communities that face
specific practical challenges.
Naysayers may challenge the
efficacy and necessity of the
HapMap project as a means to this
end [4], but few practitioners will
doubt its value and utility.
Nevertheless, without wishing to
diminish from the scale of these
achievements or the transition
represented by genome-wide
association, it is worth returning
to what the real motivation is for
genetic studies, and judging
progress by that metric.
There are three fundamental
reasons to want to map gene
variants for common disease.
These are: first, to predict risk and
therefore allow tailoring of lifestyle
choices to risk; second, to improve
understanding of disease
pathophysiology in a manner that
suggests new directions for
therapy; and third, to identify
subclasses of clinically similar
diseases that nevertheless have
different genetic etiologies and
hence should respond to different
therapies.
By the standards of these
fundamental goals whole genome
studies of common diseases have
yet to prove themselves. Quiteaside from practical challenges
in relation to regulatory oversight
and implementation of robust
genetic counseling protocols,
genome-wide association data are
currently explanatory but are not
yet usefully predictive. Even in the
most successful case, Crohn’s
Disease, with nine validated
associations, most of the genetic
risk in the population remains to be
explained, and the proportional
contribution of parSNPs to family
clustering seems to be less than
a few percent [1,5]. If there are
other factors out there, they are
unlikely to individually account for
more than one or two percent of
susceptibility, and hence some
would argue that they will be
practically and clinically irrelevant.
By contrast, it has been suggested
that pharmacogenetics is likely to
provide more immediate clinical
returns than disease genetics,
a good example of which is the
recent demonstration that HLA-B
genotype predicts hypersensitive
response to the anti HIV drug
abacavir [6].
The term parSNP serves as
a reminder that the purpose of
genome-wide association is not so
much tofind individual riskallelesas
population attributable risk factors.
Like the concept of heritability,
which applies to populations not
individuals, parSNPs are identified
by their influence averaged across
individuals within a population. We
are not aware of any claims that
common disease variants would
typically be prognostic, and
suspect that geneticistsmuchmore
commonly imagine that there are
likely dozens if not hundreds of
variants that can contribute to any
given disease. Individuals who
happen to inherit an excess of
these, and experience damning
environmental circumstances, are
more susceptible than others. It is
the constellation of factors that is
potentially predictive, not single
variants.
There are some tantalizing
suggestions from multivariate
modeling that this may be the case.
As a class, SNPs in genes involved
in steroid hormonal regulation and
cell cycle control are more
commonly associated with breast
cancer than if you query similarly
sized sets of SNPs in randomly
Dispatch
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reanalysis of a low resolution
genome-wide association for
Parkinson’s disease, which initially
came up with a single strong
candidate parSNP, implicates
genes involved in axonal guidance
as a class in the etiology of this
neurodegenerative disease [8].
The joint probability of association
of a signature involving 117 genes
with Parkinson’s disease is in the
range of 10240.
Andre´ Rzhetsky and colleagues
[9] arrived at a similar conclusion
without even looking at genotypes.
They scoured the medical records
of 1.5 million patients of the
Columbia University Medical
System and considered the overlap
in disease diagnoses for 124
relatively common diseases. After
adjusting for correlations due to
age and sex, they find striking
tendencies for certain diseases
to co-occur in individuals (for
example, autism, bipolar
depression and schizophrenia).
They even estimate that some of
these diseases are likely to share
as many as 20% or more of their
susceptibility alleles.
We are led to conclude that
genome-wide association is more
likely to have an impact with
respect to the second and third
objectives presented above.
For example, a genome-wide
association for asthma
supports increased interest
in airway remodeling
alongside inflammatory
hyper-responsiveness [10];
autophagy is implicated in the
etiology of inflammatory bowel
disease [5]; and thebipolar disorder
data [1] place the copious literature
pertaining to neurotransmitters
and synaptic transmission as
mediators of depression in a
genome-wide perspective. The
impact of genetics on disease
sub-classification is yet to be felt,
but clearly there is now good
reason to expect advances.
A remarkable but yet-to-be
remarked upon aspect of the
recent deluge of genome-wide
association data is the apparent
diversity in the yield of associations
for different diseases. Why, for
example, is it that hypertension and
bipolar disorder are devoid of the
class of highly significant hits thatcharacterize the immune-related
diseases Crohn’s disease and type
1 diabetes? A common view is that
this as essentially the luck of the
draw— some traits happen to have
polymorphisms influencing them
that are both common and
important enough to be detectable
in manageable sample sizes, and
other traits do not. A more
intriguing interpretation is that the
data are telling us that some traits
are largely resistant to the effects
of common genetic variation
whereas others are much more
susceptible.
While it is perhaps too early to
declare a clear pattern, we suspect
there may be evolutionary
explanations for the differences
amongst traits. Contrast, for
example, two quantitative
traits: blood pressure and HIV
viral load following infection. While
hypertension produced no clear
discoveries in 2000 cases [1],
a study of just 500 subjects
characterized for HIV-1 viral load
identified three variants explaining
14% of the total variation [11]. We
doubt these differences are the
luck of the evolutionary draw and
suspect they may result from
a kind of evolutionary canalization.
A key difference between HIV-1
set point and blood pressure is
that blood pressure is likely
to have been close to a
long-term optimum, whereas
this is not the case for the HIV-1
setpoint.
Canalization refers to the
observation that genetic systems
have often evolved robustness to
genetic and environmental
perturbation [12]. Expression of
phenotypic variation is suppressed
by the network of epistatic
interactions among alleles within
the normal environmental context
that an organism finds itself in.
Take the organism outside of this
buffering zone, for example, by
dramatically changing diet and
immune exposure, and cryptic
variation can be exposed [13].
Variants that under ‘normal’
circumstances would not
contribute appreciably to
disease do so in the modern
world because they push
individuals closer to the threshold
upon which the new environment
acts (Figure 1A).The possibility that
(de)canalization helps to explain
the heterogeneity of genome-wide
association results to date should
be considered. A tentative
indication that genetic buffering
may suppress the effects of
mutations that would otherwise
lead to disease is seen in the shape
of the Q-Q plots from theWellcome
Trust Case Control Consortium
study [1] (Figure 1B,C). These plots
show the relationship between
observed and expected test
statistics, and for five of the
diseases, the observed curves
deviate sharply to higher than
expected test statistic values at
the upper extreme, due to the
parSNPs. For bipolar disorder and
hypertension, by contrast, these
curves actually plateau off as
would be observed if the effects
of candidate parSNPs were
buffered.
Intriguingly, there is also
a difference in the polarity of
associations for different classes
of disease. Most of the parSNPs
are more likely tagging SNPs
than the causal sites, so it is not
clear what their relationships to
the ancestral status of the true
disease-promoting variants are.
Nevertheless, including moderate
evidence for association, almost
two thirds of all risk-associated
SNPs in the Wellcome Trust Case
Control Consortium study [1] are
ancestral, implying that the derived
allele in thehuman lineage isoffering
protection from disease. More
strikingly, for hypertension, all of the
(moderate) risk alleles are ancestral,
and for rheumatoid arthritis 10 of 12
are. The clear exception is Crohn’s
disease, for which 10 of 16 of the
risk-associated parSNPs that we
were able to polarize
unambiguously are derived.
A prediction of the
decanalization hypothesis is that
as the prevalence of a disease
increases in modern society, the
likelihood of genome-wide
association uncovering
susceptibility alleles also
increases. Inflammatory diseases
have increased in prevalence
recently, arguing that deleterious
interactions between the modern
environment and derived alleles
corrode the evolved buffering,
which in turn may expose ancestral
Current Biology Vol 17 No 21
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Figure 1. Canalization and genome-wide association.
(A) Model of effect of canalization on disease. Each genotype in a population is asso-
ciated with a level of disease susceptibility that will typically be normally distributed
but with a liability threshold indicated by the vertical broken line. Under normal envi-
ronmental or genetic circumstances (green), very few individuals are above the thresh-
old, but in an altered environment or non-equilibrium genetic circumstances (red), the
variance of the susceptibility increases, and more genotypes give rise to individuals
above the threshold, exposing hidden variation. (B) For coronary artery disease,
Crohn’s disease, types 1 and 2 diabetes, and rheumatoid arthritis, the observed asso-
ciation test statistics (negative log p-values) exceed the expected range of values
shown in light green. (C) For bipolar disorder and hypertension, by contrast, high as-
sociation scores are not seen and the Q-Q plot curve actually flattens off to a plateau,
possibly suggesting buffering.alleles to disease promotion. Our
recent demonstration of highly
significant associations of derived
alleles with HIV setpoint [11] may
be another instance of this
phenomenon. Not having been
exposed to the virus until a few
generations ago, there has been
no time for the genome to evolve
canalization, and additive variation
for viral titers segregates in human
populations.
This hypothesis puts us slightly
at odds with the recommendations
of Merikangas and Risch [14] in
relation to public health priorities
for investment in genomic
research. They argued that there
is little point in expenditure on
genome-wide association for
diseases where the genetic
contribution pales in comparison to
environmental factors, since public
health campaigns to modify
behavior or otherwise address the
environmental risk will be far more
effective than treatments thattarget genetic variation. However,
strong environmental
perturbations are precisely the
conditions under which hidden
genetic variants may be revealed
and hence under which
genome-wide association may be
most likely to succeed. The
immediate benefit of parSNPs is
not as biomarkers for personalized
medicine, but rather as entry
points into the hidden genetic text
of complex disease. A policy
consequence is that genetic
advances may, counterintuitively,
bemost obviouswhere humans are
exposed to novel environmental
exposures, including nutrition and
childhood infection. Findings in at
risk populations are likely to carry
over into canalized ones, and the
key is to seek understanding of all
facets of risk.
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